Straits Times Index
3,323.00 +8.86 (+0.27%) Nikkei
39,173.15 +368.50 (+0.95%) Hang Seng
18,015.20 -12.51 (-0.07%) FTSE 100
8,281.55 +43.83 (+0.53%) Bitcoin USD
61,116.55 -1,232.06 (-1.98%) CMC Crypto 200
1,266.68 +17.56 (+1.41%)
Precigen, Inc. (I5X.F)
| Previous close | 1.4270 |
| Open | 1.4110 |
| Bid | 1.4730 x 30000 |
| Ask | 1.5300 x 30000 |
| Day's range | 1.4110 - 1.4110 |
| 52-week range | 0.8200 - 1.6700 |
| Volume | |
| Avg. volume | 195 |
| Market cap | 359.026M |
| Beta (5Y monthly) | 1.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3600 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.50 |
Simply Wall St.Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
Precigen, Inc. ( NASDAQ:PGEN ) shareholders should be happy to see the share price up 15% in the last week. But only...
PR NewswirePrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released positive Phase 1/2 pivotal study results for the investigational PRGN-2012 off-the-shelf (OTS) AdenoVerse® gene therapy in patients with recurrent respiratory papillomatosis (RRP). Results were presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Scott
PR NewswirePrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast w
